[ Price : $8.95]
FDA grants Xenex Disinfection Services a de novo marketing authorization for the companys LightStrike+ device, a broad-spectrum ul...[ Price : $8.95]
Individuals and organizations opposed to using puberty blockers in gender identity treatment for minors ask FDA to take several st...[ Price : $8.95]
Six Epstein Becker Green attorneys analyze an FDA final guidance on informed consent that leaves the door open to future changes a...[ Price : $8.95]
X4 Pharmaceuticals files an NDA for a once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (warts, hypoga...[ Price : $8.95]
Roche says recent data from its Phase 3 ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met ...[ Price : $8.95]
FDA posts a final guidance entitled Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex (MAC): De...[ Price : $8.95]
FDA posts a draft guidance entitled Post-Warning Letter Meetings Under GDUFA that provides information on implementing the new pro...[ Price : $8.95]
Federal Register notice: FDA makes available a guidance to describe that enforcement policies will be extended for an additional y...